EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deprescribing and Anti-CGRP preventive therapy in medication-overuse headache associated with migraine: pathophysiological rationale and single-center real world evidence

Matija Sošić, Valentino Rački, Almir Fajkić, Mladen Jašić, Andrej Belančić

Frontiers in Drug Safety and Regulation · 12.08.2026 · 6

DOI: 10.3389/fdsfr.2026.1836444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Drug Safety and Regulation, online erschienen am 12.08.2026. Verfasst von Matija Sošić und 4 weiteren Autor:innen. Beteiligte Einrichtung: Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno, Rovinj, Croatia. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medication-overuse headache (MOH) associated with migraine is a biologically driven disorder involving central sensitization, maladaptive neuroplasticity, and enhanced calcitonin gene-related peptide (CGRP) signaling. While structured deprescribing addresses medication-related drivers, withdrawal alone often provides limited and unsustained benefit. Anti-CGRP preventive therapies offer targeted modulation of migraine pathways without reinforcing medication overuse. This study integrates pathophysiological insights with real-world evidence from a single-center study of 47 patients treated with combined deprescribing and anti-CGRP therapy. Clinically meaningful reductions in monthly migraine days were observed, with 85.1% achieving ≥50% reduction at 6 months and 78.7% achieving >75% reduction at 12 months. Our clinical experience also suggests that long-standing combination analgesic overuse may be associated with a slower treatment response. The present findings support a mechanism-based treatment approach and suggest that combining preventive therapy with deprescribing may optimize long-term outcomes in patients with migraine-associated MOH.

Schlagwörter

Stichwörter der Autor:innen

analgesicscalcitonin gene-related peptideheadachemedication overusemigraine disordersmonoclonal antibodiesneuroplasticity

Autor:innen und Institutionen

  • Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno, Rovinj, Croatia.
  • Faculty of Medicine, Juraj Dobrila University of Pula, Pula, Croatia.
  • Department of Neurology, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
  • Department of Neurology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
  • Department of Pathophysiology, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Department of Basic and Clinical Pharmacology and Toxicology, University of Rijeka, Faculty of Medicine, Rijeka, Croatia.

Zitieren

APA

Sošić, M., Rački, V., Fajkić, A., Jašić, M., & Belančić, A. (2026). Deprescribing and Anti-CGRP preventive therapy in medication-overuse headache associated with migraine: pathophysiological rationale and single-center real world evidence. Frontiers in Drug Safety and Regulation, 6. https://doi.org/10.3389/fdsfr.2026.1836444

Vancouver

Sošić M, Rački V, Fajkić A, Jašić M, Belančić A. Deprescribing and Anti-CGRP preventive therapy in medication-overuse headache associated with migraine: pathophysiological rationale and single-center real world evidence. Frontiers in Drug Safety and Regulation. 2026;6. doi:10.3389/fdsfr.2026.1836444

BibTeX
@article{Soi2026,
  author = {Sošić, Matija and Rački, Valentino and Fajkić, Almir and Jašić, Mladen and Belančić, Andrej},
  title = {Deprescribing and Anti-CGRP preventive therapy in medication-overuse headache associated with migraine: pathophysiological rationale and single-center real world evidence},
  journal = {Frontiers in Drug Safety and Regulation},
  year = {2026},
  volume = {6},
  doi = {10.3389/fdsfr.2026.1836444}
}
Kostenlos starten →